Study to Evaluate the Reinduction and Second Stop of TKI with Ponatinib in CML in Molecular Response (ResToP) (ResToP)
Multicenter, Open-Label, Single Arm, Phase II Exploratory Study to Evaluate the Reinduction and Second Stop of TKI with Ponatinib in CML in Molecular Response (ResToP)
Sponsor: Apices Soluciones S.L.
Listed as NCT04160546, this PHASE2 trial focuses on Chronic Myeloid Leukemia, Chronic Phase and remains ongoing. Sponsored by Apices Soluciones S.L., it has been updated 16 times since 2020, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
16 versions recorded-
Sep 2025 — Present [monthly]
Active Not Recruiting PHASE2
-
Feb 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE2
-
Sep 2024 — Feb 2025 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Jan 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
▶ Show 11 earlier versions
-
Mar 2023 — Jan 2024 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Sep 2022 — Mar 2023 [monthly]
Recruiting PHASE2
-
Mar 2022 — Sep 2022 [monthly]
Recruiting PHASE2
-
Oct 2021 — Mar 2022 [monthly]
Recruiting PHASE2
-
Sep 2021 — Oct 2021 [monthly]
Recruiting PHASE2
-
Feb 2021 — Sep 2021 [monthly]
Recruiting PHASE2
-
Jan 2021 — Feb 2021 [monthly]
Recruiting PHASE2
-
Nov 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Apr 2020 — Nov 2020 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jan 2020 — Apr 2020 [monthly]
Not Yet Recruiting PHASE2
-
Dec 2019 — Jan 2020 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Apices Soluciones S.L.
- Fundacion CRIS de Investigación para Vencer el Cáncer
- Incyte Biosciences UK
For direct contact, visit the study record on ClinicalTrials.gov .